Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-04-05 @ 10:16 PM
Study NCT ID:
NCT07449234
Status:
RECRUITING
Last Update Posted:
2026-03-13
First Post:
2026-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Sponsor:
Janssen-Cilag Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-02-09
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2026-02-27
First Submit QC Date:
None
Study First Post Date:
2026-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-12
Last Update Post Date:
2026-03-13
Last Update Post Date Type:
ACTUAL